Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin delivery via nanoporous microneedle array in healthy volunteers
NL-OMON48081Active, not recruiting
- Sponsor
- MyLife Technologies
- Start
- Jun 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of desmopressin in arginine vasopressin deficiency (CDI), nocturnal enuresis (NE), hemophilia A and 1 more (3 arms), sponsored by MyLife Technologies. Primary endpoints: Adverse events, Vital signs and 14 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
desmopressin
03
Conditions
arginine vasopressin deficiency (CDI)nocturnal enuresis (NE)hemophilia Avon Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON48081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48081.